{"id":"W4401896808","doi":"10.1016/s2152-2650(24)01551-9","title":"ABCL-711 Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Brentuximab vedotin; Lenalidomide; Diffuse large B-cell lymphoma; Rituximab; Internal medicine; Oncology; Refractory (planetary science); Lymphoma; Multiple myeloma; Hodgkin lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00152619,0.0007794964,0.001493246,0.0003710783,0.0002291704,0.001005396,0.0007277938,0.0006452113,0.001129945],"category_scores_gemma":[0.0009496413,0.0003824833,0.001029012,0.000453431,0.0005113868,0.0008196704,0.0003162454,0.001819461,0.0004410767],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009866933,"about_ca_system_score_gemma":0.0009150509,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001646182,"about_ca_topic_score_gemma":0.004133209,"domain_scores_codex":[0.999448,0.0002886661,0.00003313427,0.00007369662,0.00006615264,0.00009039485],"domain_scores_gemma":[0.999474,0.0001343901,0.0001148897,0.00003443728,0.00002827009,0.0002141509],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.582951,0.02428879,0.05401057,0.0009455548,0.005878669,0.0004154404,0.0004018423,0.004612122,0.02508645,0.0002767669,0.00542805,0.2957048],"study_design_scores_gemma":[0.454907,0.3061591,0.2084312,0.0001954845,0.005719902,0.001369322,0.0003454621,0.005173954,0.005476824,0.0005627509,0.01154216,0.0001168664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925805,0.00528178,0.0001484841,0.000301322,0.00005894988,0.0001592505,0.0003833918,0.00003972729,0.001046541],"genre_scores_gemma":[0.9947519,0.002440939,0.0004083595,0.0004412359,0.00008137267,0.0001461134,0.001033432,0.00001628532,0.0006805311],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001646182,"threshold_uncertainty_score":0.008071363,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01621373982619982,"score_gpt":0.2924634421678154,"score_spread":0.2762497023416156,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}